Editorial

Bisphosphonates and Bone diseases: past, present and future
Bisphosphonates are stable analogues of the naturally-occuring inorganic pyrophosphate and unlike PPi, they are resistant to hydrolysis due to a carbon atom bridging the two phosphonate groups. Whether the first bisphosphonates formerly termed for bisphosphonate in rheumatic diseases [12] . Indeed, bisphosphonates could also have others properties through a specific analgesic or anti-inflammatory effect. Thus, rheumatic diseases like rheumatoid arthritis, spondylarthritis or SAPHO syndrome that are associated with bone loss could be good candidates for bisphosphonate therapy similarly to other noninflammatory rheumatic diseases like bone osteonecrosis, algodystrophy, fibrous dysplasia or neuropathic osteoarthropathy.
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